

Impact of SARS-CoV-2 infection and COVID-19 on patients with inborn errors of immunity



Stuart G. Tangye, PhD, for the COVID Human Genetic Effort consortium* *Darlinghurst and Randwick, Australia*

Since the arrival of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in December 2019, its characterization as a novel human pathogen, and the resulting coronavirus disease 2019 (COVID-19) pandemic, over 6.5 million people have died worldwide—a stark and sobering reminder of the fundamental and nonredundant roles of the innate and adaptive immune systems in host defense against emerging pathogens. Inborn errors of immunity (IEI) are caused by germline variants, typically in single genes. IEI are characterized by defects in development and/or function of cells involved in immunity and host defense, rendering individuals highly susceptible to severe, recurrent, and sometimes fatal infections, as well as immune dysregulatory conditions such as autoinflammation, autoimmunity, and allergy. The study of IEI has revealed key insights into the molecular and cellular requirements for immune-mediated protection against infectious diseases. Indeed, this has been exemplified by assessing the impact of SARS-CoV-2 infection in individuals with previously diagnosed IEI, as well as analyzing rare cases of severe COVID-19 in otherwise healthy individuals. This

approach has defined fundamental aspects of mechanisms of disease pathogenesis, immunopathology in the context of infection with a novel pathogen, and therapeutic options to mitigate severe disease. This review summarizes these findings and illustrates how the study of these rare experiments of nature can inform key features of human immunology, which can then be leveraged to improve therapies for treating emerging and established infectious diseases. (*J Allergy Clin Immunol* 2023;151:818-31.)

Key words: SARS-CoV-2, COVID-19, inborn errors of immunity, primary immune deficiencies, immune dysregulation, type I IFN signaling, cytokine storm

Inborn errors of immunity (IEI) are diseases caused by germline pathogenic variants, typically in single genes.¹⁻⁴ IEI have an incidence of ~1 per 5,000 to 10,000 individuals.¹⁻⁵ Currently, pathogenic variants in more than 480 genes have been identified that cause IEI. These variants can lead to loss of expression, complete (null) or partial (hypomorphic) loss of function, gain of function (GOF; hypermorphic), haploinsufficiency, or dominant negative function of the encoded protein. IEI can present as autosomal dominant (AD; heterozygous variants), autosomal recessive (AR; homozygous/compound heterozygous variants), or X-linked (XL) recessive (hemizygous in male subjects; homozygous or heterozygous with skewed X inactivation in female subjects) conditions.^{4,6} However, some IEI have incomplete penetrance, with a significant proportion of individuals carrying some pathogenic variants compromising protein function remaining unaffected.⁷ The mechanism or mechanisms underlying incomplete penetrance remain unclear but may involve epistatic effects of modifier genes, epigenetics, and/or variants in additional genes.⁷ It is also worth noting that a monogenic cause for the most common IEI—common variable immunodeficiency (CVID)—has only been determined for ~20-30% of affected individuals,⁸ thus suggesting that most cases of CVID are likely to be oligo- or polygenic.

IEI are characterized by defects in immune cell development, and/or impaired innate and adaptive immune function of hematopoietic and nonhematopoietic cells. Consequently, affected individuals are highly susceptible to severe, recurrent, and sometimes fatal infections.^{4,6} As a result of this immunodeficient state, vaccine efficacy can also be compromised in IEI, resulting in affected individuals having modest, if any, vaccine-induced immunity against infectious diseases. Thus, IEI patients continue to be susceptible to infection as well as being vulnerable to disease as a result of live-attenuated vaccines.⁹

Although historically considered to be immune deficiencies manifesting as infections, the clinical spectrum of IEI is

From the Garvan Institute of Medical Research, Darlinghurst; St Vincent's Clinical School, University of New South Wales Sydney, Randwick; and the Clinical Immunogenomics Research Consortium of Australasia (CIRCA).

*Members of the COVID Human Genetic Effort consortium are listed in the Acknowledgments at the end of the article.

S.G.T. is supported by an Investigator Grant awarded by the National Health and Medical Research Council of Australia, the Allergy & Immunology Foundation of Australia, the Jeffrey Modell Foundation, and a University of New South Wales Sydney COVID Rapid Response Initiative grant. H.C.S. and L.D.N. (listed under the COVID Human Genetic Effort consortium) are supported by the Division of Intramural Research of the National Institute of Allergy and Infectious Diseases, NIH. J.L.C. (listed under the COVID Human Genetic Effort consortium) is supported by the NIH (R01AI088364, R01AI163029, UL1TR001866), Fisher Center for Alzheimer's Research Foundation, Meyer Foundation, JPB Foundation, French National Research Agency (ANR-10-IAHU-01, ANR-10-LABX-62-IBEID, ANR-20-CE93-003, ANR-20-CO11-0001, French Foundation for Medical Research (EQU201903007798), the ANRS-COV05, European Union's Horizon 2020 Research and Innovation Program (824110; EASI-genomics), HORIZON-HLTH-2021-DISEASE-04 Program (01057100; UNDINE), the ANR-RHU COVIFERON Program (ANR-21-RHUS-08), the Square Foundation, Grandir - Fonds de solidarité pour l'enfance, the Fondation du Souffle, the SCOR Corporate Foundation for Science, and French Ministry of Higher Education, Research, and Innovation (MESRI-COVID-19).

Disclosure of potential conflict of interest: The author declares no relevant conflicts of interest.

Received for publication September 29, 2022; revised November 2, 2022; accepted for publication November 4, 2022.

Available online December 13, 2022.

Corresponding author: Stuart G. Tangye, PhD, Garvan Institute of Medical Research, 384 Victoria St, Darlinghurst, NSW, 2010 Australia. E-mail: s.tangye@garvan.org.au.

The CrossMark symbol notifies online readers when updates have been made to the article such as errata or minor corrections

0091-6749/\$36.00

© 2022 American Academy of Allergy, Asthma & Immunology

<https://doi.org/10.1016/j.jaci.2022.11.010>

Abbreviations used

APECED:	Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy
AR:	Autosomal recessive
BTK:	Bruton tyrosine kinase
CFR:	Case fatality rate
COVID-19:	Coronavirus disease 2019
CVID:	Common variable immunodeficiency
GOF:	Gain of function
ICU:	Intensive care unit
IEI:	Inborn errors of immunity
JAK:	Janus kinase
mAb:	Monoclonal antibody
SARS-CoV-2:	Severe acute respiratory syndrome coronavirus 2
XL:	X linked
XLA:	XL agammaglobulinemia

extremely broad, with autoimmunity, autoinflammatory diseases, allergy, bone marrow failure, and/or malignancy also being common maladies of patients.^{1,3,4,6,10,11} Although most are individually rare, IEI are collectively common⁵ and have enabled the delineation of fundamental roles of individual genes, proteins, signaling pathways, and cell types in immune cell development; immune homeostasis and regulation; antitumor immunity; and host defense against infectious diseases.¹⁻³ Thus, IEI provide insights into the molecular pathogenesis of more common diseases and have led to the development of targeted therapies for various immune dyscrasias.^{1-3,12}

SARS-CoV-2 AND THE COVID-19 PANDEMIC

Coronaviruses have caused pandemics in the human population for decades.¹³ Certainly we would have a short memory if we failed to recall the deadly toll of the original SARS coronavirus outbreak in 2002-3.¹³ In December 2019, the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged from Wuhan, China, and then spread rapidly to cause a catastrophic global pandemic.¹⁴ At the time of writing, more than 650 million people have been infected and at least 6.6 million people have died from SARS-CoV-2 infection (www.covid19.who.int/, www.worldometers.info/coronavirus/). The clinical spectrum of coronavirus disease 2019 (COVID-19) due to SARS-CoV-2 infection ranges from asymptomatic to life-threatening disease. The global case fatality rate (CFR) due to SARS-CoV-2 infection is currently ~1.1%, but this varies widely across different countries, ranging from 0.1% to 5%, and even up to 10% to 15% for some regions (www.ourworldindata.org/grapher/deaths-covid-19-vs-case-fatality-rate). Importantly, early during the pandemic, when viral screening was restricted to symptomatic individuals and vaccines were still 12 to 18 months away, the average global CFR was 5% to 7%, and as high as 10% to 20% in the United Kingdom and some European countries.^{15,16} (www.ourworldindata.org/grapher/deaths-covid-19-vs-case-fatality-rate).

Several risk factors have been identified for developing severe disease, as defined by the World Health Organization. These include primarily age, with the frequency of severe cases/death escalating with each decade of increasing age. For example, the mortality rate for people aged <50 years was <1.0%; for

individuals aged 60-80 or more years, the mortality rate was ~4% to 25%. Male sex as well as comorbidities such as cardiovascular/pulmonary disease, obesity, diabetes, and liver/kidney dysfunction also have an impact, albeit less than age.¹⁶⁻¹⁹ Correlates of severe disease and mortality include lymphopenia, increased levels of inflammatory mediators, cytokines, chemokines,^{18,20-26} and complement components,²⁷⁻²⁹ which indicate the intense immune activation and inflammation that can lead to severe and potentially fatal SARS-CoV-2-induced cytokine storm and consequent tissue pathology.

In healthy individuals, SARS-CoV-2 infection induces functional CD4⁺ and CD8⁺ T cells and memory B cells specific for viral epitopes, as well as neutralizing antibodies.³⁰⁻³⁹ These correlates of protective immunity are detectable 1 or 2 weeks after infection and persist at peak levels for 3 to 4 months. However, in most cases, levels of neutralizing IgG and of SARS-CoV-2-specific memory B cells and T cells dramatically wane 8 to 12 months after infection,^{32-34,36-40} potentially compromising host defense against subsequent infections. Furthermore, several SARS-CoV-2 variants that have acquired mutations in the immunodominant spike domain, thus rendering these variants less susceptible to antibody-mediated neutralization, have emerged.⁴¹ Waning of acquired immunity after natural infection, combined with immune-escape variants, are a significant challenge in controlling SARS-CoV-2 infection, resulting in COVID-19 continuing to represent a significant global health risk.

SARS-CoV-2 INFECTION, COVID-19, AND IEI

Since the beginning of the pandemic, it was recognized that people diagnosed with an IEI were potentially at risk of developing severe COVID-19. Over the past 2 years, outcomes of SARS-CoV-2 infection have been reported for ~1330 individuals with IEI. These studies range from reports of single cases or small numbers of patients⁴²⁻⁸⁸ to cohort studies from Iran,⁸⁹⁻⁹¹ Turkey,⁹²⁻⁹⁴ Brazil,^{95,96} Israel,⁹⁷ Italy,⁹⁸⁻¹⁰¹ Spain,¹⁰² the United Kingdom,^{15,103,104} Mexico,¹⁰⁵ Denmark,^{106,107} Poland,¹⁰⁸ the Czech Republic,¹⁰⁹ France,¹¹⁰ and the United States,¹¹¹⁻¹¹⁴ as well as an international survey of 94 patients followed in 12 countries.¹¹⁵ These studies have revealed key outcomes of SARS-CoV-2 infection in IEI and defined fundamental requirements for host defense against infection.

Patients with IEI infected with SARS-CoV-2

Affected patients have been found to represent most, if not all, categories of IEI as defined by the International Union of Immunological Societies Committee (Table I).⁶ Of the ~1330 patients reported so far, approximately 60% have antibody deficiencies, consistent with antibody deficiency being the most common IEI.^{6,8} This includes CVID, hypogammaglobulinemia, and specific antibody and immunoglobulin subclass deficiencies due to unknown genetic causes⁸ (~600 cases), as well as XL (*BTK* pathogenic variants) and AR (eg, *TCF3* pathogenic variants) agammaglobulinemia (~110 cases) and a series of patients with pathogenic variants in single genes known to disrupt B-cell function and humoral immunity, such as *NFKB1*, *NFKB2*, *PIK3CD*, or *PIK3R1* (Table I). Outcomes of SARS-CoV-2 infections have also been reported for patients with the following:

- Severe combined (*JAK3*, *RAG*, *IL7RA*, *DCLRE1C*) or combined (*CD40LG*, *RASGRP1*, *RELB*, *STK4*, *WAS*, *ICOS*, *ATM*, *IKBKG*, *STAT3 DN*, *PGM3*) immunodeficiencies.

TABLE I. SARS-CoV-2 infection in defined IEI

Type of IEI	Gene defect/IEI	Approximate no. of patients	Study or studies	
Severe combined immunodeficiency (n = 25)	<i>JAK3</i>	1	70	
	<i>RAG</i>	3	92, 97, 115	
	<i>IL7RA</i>	1	91, 94	
	<i>DCLRE1C</i>	1	49	
	<i>IL2RG</i>	4	77, 95, 115	
	<i>CD3D</i>	1	105	
Combined immunodeficiency (n = 91)	Not specified	15	95, 99, 108	
	<i>STAT3 DN</i>	7	103, 109, 115, 176	
	<i>PGM3</i>	1	102, 115	
	<i>ARPC1B</i>	1	47, 105, 115	
	<i>WAS</i>	8	47, 48, 95, 99, 100, 103, 105, 108, 109, 115	
	<i>ZAP70</i>	1	115	
	<i>CD40L</i>	9	94, 95, 97, 103, 109, 111, 116, 143	
	<i>RASGRP1</i>	1	92	
	<i>CARD11</i>	1	92, 103	
	<i>RELB</i>	3	97, 116	
	<i>STK4</i>	1	89	
	<i>DNMT3B/NBS1</i>	4	89, 91, 94	
	<i>ICOS</i>	1	15, 103	
	<i>IKBKG (NEMO)</i>	3	72, 78, 94	
	<i>ATM</i>	11	91, 92, 94, 99, 100, 102, 103, 108	
	Di George syndrome	16	99, 100, 108	
	Not specified	23	89, 92, 94, 95, 99, 103, 108	
	Predominantly antibody deficient (n = 714)	CVID*	589	51, 52, 58, 71, 75, 83, 92, 94, 95, 97-100, 102-109, 111-115, 143
		<i>BTK</i>	98	15, 46, 51, 53, 55, 60, 61, 66, 73, 85, 86, 91, 92, 94, 95, 97-100, 102-105, 108, 109, 111, 115, 116, 139, 140, 143
AR agammaglobulinemia		9	99, 100, 115	
<i>PIK3R1/PIK3CD</i> GOF		7	64, 82, 91, 95, 99, 100, 115	
<i>NFKB1</i>		4	15, 91, 103, 111, 115	
<i>NFKB2</i>		3	43, 103, 115, 143	
<i>IKZF1</i>		1	91	
Immune dysregulation (n = 64)		<i>AIRE (APS1/APECED)</i>	29	57, 84, 94, 118, 122, 149
		<i>CTLA4</i>	7	15, 97, 103, 115, 177
		<i>LRBA</i>	3	92, 97, 115
	<i>SOCS1</i>	1	76	
	<i>STAT3</i> GOF	1	111	
	<i>RAB27A</i>	1	89	
	<i>CD70</i>	1	89	
	ALPS	5	95, 99, 102, 108	
	<i>XLP (XIAP, SH2D1A)</i>	4	63, 95, 108, 109, 115	
	<i>PRKCD</i>	1	115	
	<i>RLTPR/CARMIL2</i>	2	94	
	<i>CD137</i>	1	94	
	<i>STXBP2</i>	2	88, 94	
	Not specified/other	6	92, 99, 105, 108	
	Phagocytic defects, bone marrow failure (n = 36)	Chronic granulomatous disease (<i>CYBB; NCF2</i>)	28	15, 59, 89, 95, 97, 102, 103, 105, 108, 115
<i>GATA2</i>		2	15, 103, 115	
<i>DNAJC21</i>		1	115	
Not specified/other		5	92, 99	
Innate immune defects (n = 75)		<i>TLR3/UNC93B/TRIF/IRF3/IRF7/IRF9/TBK1</i>	23	65, 68, 69, 120, 123
	<i>IFNAR1/2</i>	7	42, 56, 87, 126	
	<i>STAT1/TYK2</i>	2	126	

(Continued)

TABLE I. (Continued)

Type of IEI	Gene defect/IEI	Approximate no. of patients	Study or studies
	<i>TLR7</i>	22	90, 124-126
	<i>MYD88/IRAK4</i>	8	45, 81, 95, 99, 102
	<i>IFNGR1/IFNGR2/IL12RB1</i>	5	54, 79, 95, 111, 115
	<i>STAT1</i> GOF	6	50, 92, 95, 102, 109, 115
	<i>CXCR4</i> GOF	2	94, 95
Autoinflammatory disorders (n = 96)	<i>MEFV</i>	68	93, 95, 110, 115
	<i>IL1RN</i>	1	89
	Aicardi-Goutières syndrome (<i>RNASEH2B, SAMHD1</i>)	5	15, 99, 100, 115
	<i>TNFAIP3</i>	1	15
	<i>NLRP1, NLRP3, NLRP12</i>	3	91, 95
	<i>IL36RN</i>	1	74
	<i>ADA2</i>	1	94
	Not specified/other	16	95, 108
Complement deficiencies (n = 55)	Hereditary angioedema (pathogenic <i>SERPING</i> variants), C3 deficiency, other	55	15, 91, 95, 96, 109
Phenocopies of IEI	Good syndrome	13	83, 100, 103, 105, 109
	Autoantibodies to type I IFNs	Many!	128-136

*Including hypogamma, immunoglobulin subclass deficiency, and specific antibody deficiency.

- Immune dysregulatory disorders (*STAT3* GOF, *AIRE*, *CTLA4*, *CD70*, *LRBA*, *RAB27A*, *SH2D1A*, *XIAP*, *RLTPR/CARML2*, *CD137*, *STXBP2*, *ALPS*).
- Phagocytic defects (chronic granulomatous disease, *GATA2*).
- Innate immune defects (*IFNGR1*, *IFNGR2*, *IFNAR1*, *IFNAR2*, *IL12RB1*, *IRAK4*, *MYD88*, *STAT1* GOF, *CXCR4*, *TBK1*, *TLR3*, *TLR7*, *IRF3*, *IRF7*, *IRF9*).
- Autoinflammatory disorders (*MEFV*, *TNFAIP3*, *IL36R*, *ADA2*).
- Complement deficiencies.
- Phenocopies of IEI.

A complete reference listing is provided in Table I.

Clinical features in IEI after SARS-CoV-2 infection

The clinical presentation of SARS-CoV-2 infection in patients with IEI resembled that of the general population^{16,19} inasmuch that symptoms frequently include fever, cough, headache, upper respiratory symptoms, fatigue, and dyspnea.^{15,89,91,92,94,95,97,99,102,103,105,106,108,109,115} Similarly, risk factors for hospital/intensive care unit (ICU) admission and developing severe and/or fatal disease were also consistent with those determined from studies of the general population. Thus, the most severe disease was observed in older patients with IEI as well as those with pre-existing comorbidities, such as previous infection; lung, kidney, heart, or gut disease, diabetes, and obesity; or after solid organ or hematopoietic stem cell transplantation.^{43,58,89,91,92,94,95,98,103,105,106,108,111,112,115} Other predictors of severe disease in IEI patients included leukopenia (reduced numbers of B, CD4⁺ T, and natural killer cells) and hypogammaglobulinemia/low IgG trough levels before infection, and increased levels of markers of systemic inflammation after infection.^{43,46,58,66,103,109,111,114} Interestingly, and similar to the general population, ~10% to 20% of infected IEI patients were asymptomatic, and up to another ~30% to 50% developed only mild disease.^{15,89,90,92-95,97-106,108-115}

Despite such similarities in disease presentation and risk factors for the general population and IEI patients, there were notable differences. First, the age of affected IEI patients was markedly younger than the general population (~28 years vs ~50-plus years).^{16,44,79,81,84,89,91,93-95,100,102-104,108-110,115} There were also differences in age at infection for different IEI. Thus, SARS-CoV-2-infected patients with COVID, periodic fevers, or complement defects were generally older, and patients with defects in innate immune cell signaling due to pathogenic variants in *IRAK4*, *MYD88*, or *IFNAR1/IFNAR2* were generally younger, than the entire cohort of published IEI patients (Fig 1, A). Second, the proportion of IEI patients admitted to ICU—including younger individuals—was substantially higher than the general population (10-30% vs 2-5%).^{15,16,44,81,91,92,94,102,105,109,111,115} Third, duration of disease—likely a result of prolonged viremia and virus shedding—was longer (1-6 months vs 1-2 weeks), and the likelihood of reinfection was greater, than observed for the general population.^{46,55,59,77,83,84,92,99,100,104,106,107,116} Thus, COVID-19 generally manifests clinically at a younger age, runs a more protracted course, and has a more severe outcome requiring hospitalization and/or ICU admission in many individuals with IEI compared to the epidemiology of SARS-CoV-2 infection in the general population (Fig 2).^{16,44} This is reminiscent of findings for SARS-CoV-2 infection in patients with cystic fibrosis. Here, it was found that many cystic fibrosis patients had mild disease and common risk factors such as diabetes and previous solid organ transplantation, but subgroups of patients exhibited increased hospitalization rates and younger age at presentation relative to the general population.¹¹⁷

Mortality due to SARS-CoV-2 infection in IEI

Depending on the country or region where different studies have been performed, as well as the size of the cohort being investigated, the CFR after SARS-CoV-2 infection in patients with IEI is highly variable, being 0,^{97,102,106,113,114} 2% to 5%,^{99,101,107-109} 5% to 10%,^{92,95,103,104} 15% to 20%,^{105,112} 20% to 30%,^{94,111,118} and >30%.^{15,89,91} From all available published studies, 113 of 1328 patients with IEI died after SARS-CoV-2




FIG 1. Features of cohorts of patients with IEI and SARS-CoV-2 infection. **(A)** Age of patients with the indicated IEI. Data are shown as median ages and quartiles for each patient group. Values above each data set represent the mean ages of patients with the indicated IEI. **(B)** CFR for all IEI patients, as well as range for the CFR in the general population (www.covid19.who.int/, www.worldometers.info/coronavirus/). Values in each patient group represent the number of deaths/total number of patients with the indicated IEI. *Agamma*, Agammaglobulinemia; *AIRE*, patients with APECED; *ATM*, ataxia telangiectasia; *C' def*, complement deficiency; *CGD*, chronic granulomatous disease; *FMF*, familial Mediterranean fever; *IFNAR1/2*, patients with pathogenic variants in type I IFN receptors; *IRF7*, *MYD88/IRAK4*, patients with pathogenic variants in *IRF7* or *MYD88/IRAK4* that disrupt type I IFN signaling.




FIG 2. Consequences and outcomes of SARS-CoV-2 infection in patients with IEI.

infection, resulting in an overall CFR of 8.5% (Fig 1, B). Remarkably, this is highly similar to the CFR reported by Meyts et al¹¹⁵ for an international survey of 94 patients with a broad range of IEI recruited from 12 countries (9.4%). The significant variability in CFR reported for many studies likely reflects the type of cohort being analyzed (eg, children vs adults; predominantly CVID due to unknown genetic defects vs severe combined immunodeficiency/combined immunodeficiency),¹⁰⁸ the predominant SARS-CoV-2 variant at the time of study,⁴¹ the burden of SARS-CoV-2 infection in different countries and the relative impact this had on the respective health care systems, and the differences in

screening for SARS-CoV-2 infection across the population. It is also important to note that the ~500 IEI described exhibit enormous diversity⁶—so much so that it is challenging to draw conclusions when assessing these patient cohorts with limited granularity. It is also likely that some IEI will result in greater predisposition to severe COVID-19, while others may even be protective,¹¹⁹ thereby obscuring the overall severity of some IEI.

While it is difficult to make a direct comparison between CFR for IEI and the general population, this has been addressed for some countries. In Brazil,⁹⁵ Italy,^{95,99-101} and the United Kingdom,¹⁰³ the CFR in IEI was ~2- to 4-fold greater than the



		Mediators of host defense	
Cell types:	 <p>Plasmacytoid DC</p> <p>Respiratory epithelial cell</p> <p>type I IFN</p>	 <p>Naive</p> <p>Memory</p> <p>Plasma cell</p> <p>IgM, IgG, IgA</p>	
Function:	<ul style="list-style-type: none"> • rapid production of type I IFNs by immune (plasmacytoid DCs) and non-immune (epithelial) cells in response to SARS-CoV-2 exposure 	<ul style="list-style-type: none"> • Ag-naïve B cells differentiate into memory B cells that rapidly respond following re-exposure/infection, and plasma cells producing neutralizing anti-SARS-CoV-2 specific IgG/IgA 	
Mechanisms of disease pathogenesis due to cellular defects:	<ul style="list-style-type: none"> • inborn errors that impair production of (<i>TLR3</i>, <i>TLR7</i>, <i>UNC93B1</i>, <i>TICAM1</i>, <i>TBK1</i>, <i>IRF3</i>, <i>IRF7</i>) or responses to (<i>IFNAR1/2</i>, <i>TYK2</i>, <i>STAT2</i>, <i>IRF7</i>) type I IFN • neutralizing autoAbs against type I IFNs ($IFN\alpha$, ω) 	<ul style="list-style-type: none"> • inborn errors affecting: <ul style="list-style-type: none"> - B cell development (eg <i>BTK</i>) - B cell function/differentiation • B-cell depletion therapy (rituximab) 	
Impact of impaired function on host defense	<ul style="list-style-type: none"> • severe, life-threatening, often fatal, SARS-CoV-2 infection • break through infection post-vaccination 	<ul style="list-style-type: none"> • severe and/or prolonged disease • increased risk of re-infection 	
Treatments to manage cellular deficiencies/defects:	<ul style="list-style-type: none"> • $IFN\alpha$ (<i>TLR3</i>, <i>TLR7</i>, <i>UNC93B1</i>, <i>TICAM1</i>, <i>TBK1</i>, <i>IRF3</i>, <i>IRF7</i>) • $IFN\beta$ (not affected by autoAbs to type I IFNs) • plasma exchange to reduce levels of anti-IFN autoAbs 	<ul style="list-style-type: none"> • convalescent plasma • anti-SARS-CoV-2 mAbs 	

FIG 3. Critical roles of innate and adaptive immune cells in host defense against SARS-CoV-2 infection and disease pathogenesis.

general population. More strikingly, though, were findings from Iran, Italy, the United Kingdom, and an international study that the CFR for IEI patients aged 20-60 years or 60-75 years was 20-50 times or 2.5-5 times greater, respectively, than the general population.^{91,99,103,115} Furthermore, while the absolute number of patients analyzed is relatively small, the CFR for IEI patients aged 0-19 years is also much greater—possibly up to 100 times—than this age group in the general population.^{91,99,103,115} Consequently, the overall average age at death due to SARS-CoV-2 infection in IEI patients is much younger than the general population (Fig 2; ~50 years vs ~80 years).^{16,44,79,81,84,89,91,93-95,100,102-104,109,110,115} Thus, in addition to IEI patients' generally presenting with COVID-19 at a younger age and a greater proportion requiring admission to ICU than the general population, the mortality rate of SARS-CoV-2 infection is greater in IEI, especially at ages where SARS-CoV-2 has a very low—even negligible—CFR in the general population (Fig 2).^{16,91,99,103,115}

INNATE IMMUNE DEFECTS PREDISPOSE TO SEVERE AND FATAL SARS-CoV-2 INFECTION

When comparing different IEI, there was often no correlation between the type of IEI and severity of disease/death after SARS-CoV-2 infection. For instance, the CFR for COVID-

agammaglobulinemia, or chronic granulomatous disease were 7.2%, 6.2%, and 7.7%, respectively, compared to 8.5% for all IEI patients reported to date (Fig 1, B). However, there were several striking exceptions. First, although only few individuals have been identified, AR-pathogenic variants in *IFNAR1* or *IFNAR2*, encoding individual receptor subunits for type I IFNs, resulted in lethal COVID-19 in 4 (57%) of 7 patients (Fig 1, B) and an average age at death of 11.8 years.^{42,56,87,120} Second, SARS-CoV-2 infection was severe in most patients with autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) as a result of biallelic pathogenic *AIRE* variants. These individuals develop neutralizing autoantibodies against a range of cytokines, including type I IFN.¹²¹ In the setting of SARS-CoV-2 infection of APECED patients, rates of hospitalization (72%, 21/29), ICU admission (59%, 17/29), and death (13.8%, 4/29)^{57,84,115,118,122} were higher than all IEI patients as well as the general population (Fig 1, B).^{16,19} Third, patients with biallelic pathogenic variants in *MYD88*, *IRAK*, or *IRF7*—which function downstream of virus-sensing Toll-like receptors to induce production of type I IFNs by dendritic cells—experience severe COVID-19, with 5 of 8 *MYD88/IRAK*-deficient and all 5 *IRF7*-deficient SARS-CoV-2-infected individuals developing COVID-19 pneumonia, requiring hospitalization and/or admission to ICU; 1 of 5 *IRF7*-deficient patient died

(Fig 1, B).^{45,81,95,99,102,120,123} Thus, genetic lesions or autoantibodies that compromise innate immunity by disrupting production or function of type I IFNs underpin severe, life-threatening, and often fatal SARS-CoV-2 infection (Fig 3).

These findings have been validated by a forward genetics approach. Whole-exome and -genome sequencing of adults and children who developed severe and/or life-threatening SARS-CoV-2 infection/COVID-19 identified pathogenic variants in genes involved in type I IFN signaling. These include genes required for the production of (*TLR3*, *TLR7*, *UNC93B1*, *TICAM1*, *TBK1*, *IRF3*, *IRF7*) or responses to (*IFNAR1*, *IFNAR2*, *TYK2*, *STAT2*, *IRF7*) type I IFN produced by plasmacytoid dendritic cells or respiratory epithelial cells after viral infection.^{65,90,120,123-126} Overall, genetic variants in the type I IFN signaling pathway were the cause of severe COVID-19 in ~3% of adults and ~10% of children (Fig 3).^{120,126,127}

Parallel to these genetic studies was the discovery that neutralizing autoantibodies specific for type I IFNs cause severe COVID-19 in 10% to 20% of otherwise healthy individuals infected with SARS-CoV-2.¹²⁸⁻¹³⁷ Interestingly, these autoantibodies were: (1) predominantly directed against IFN- α and IFN- ω but not IFN- β ; (2) found in increasing proportions of affected patients with each decade of life; (3) associated with disease severity, prolonged virus clearance, and admission to ICU; (4) inversely related to serum levels of type I IFNs and interferon-stimulated gene signatures in myeloid cells;^{78,128-137} and (5) enriched in affected male subjects compared to female subjects across different age intervals. This, together with XL *TLR7* deficiency, may contribute to the increased incidence of hospitalization and severe COVID-19 in male versus female subjects. These genetic and serologic studies unequivocally identified a fundamental nonredundant role for type I IFN-dependent immunity against SARS-CoV-2 infection, with 20% to 25% of cases of severe and life-threatening COVID-19 resulting from defective type I IFN production or function (Fig 3).

Additional anecdotal data have also linked impaired type I IFN-dependent immunity with susceptibility to SARS-CoV-2 infection. First, the CFR for autoinflammatory conditions such as Aicardi-Goutières syndrome or familial Mediterranean fever was lower than that for all reported cases of IEI (4.4% vs 8.5%; Fig 1, B).^{15,93,95,99,110,115} Thus, increased basal type I IFN signaling in these conditions may enable prompt host defense against SARS-CoV-2. Second, a recent study of patients with systemic lupus erythematosus, which is characterized by overproduction of type I IFNs, found that a subset of these patients also produced autoantibodies against type I IFNs. Remarkably, while these autoantibody-positive patients were less likely to develop active lupus disease, members of this same group were at increased risk of severe viral infections and sequelae including COVID-19 pneumonia.¹³⁸

B CELLS AND PROTECTIVE IgG IN HOST DEFENSE AGAINST SARS-CoV-2

The study of COVID-19 in IEI provides an elegant opportunity to define redundant and nonredundant requirements for host defense against SARS-CoV-2. Initial studies found that patients with congenital B-cell deficiency and agammaglobulinemia had relatively mild disease and prompt recovery after SARS-CoV-2 infection.^{51,73,92,97,98} This led to a suggestion that B cells and

neutralizing IgG may not be necessary for controlling SARS-CoV-2 infection and preventing severe COVID-19.⁹⁸ Consistent with this, the CFR for XL/AR agammaglobulinemia patients is lower than all IEI patients (6.2%, 6/97, vs 8.5%, Fig 1, B). However, COVID-19 and SARS-CoV-2 viremia/virus shedding are prolonged in many B-cell-deficient/agammaglobulinemia patients, resulting in pneumonia requiring extended or multiple hospital stays, as well as numerous treatments to control viral infection.^{46,55,60,61,85,86,99,100,104,116,139} There have also been reports of chronic and/or repeated infections with worse outcomes than primary infection before vaccination, as well as breakthrough infections after vaccination in some XL agammaglobulinemia (XLA) patients.^{100,104,109,116,140} Similar observations in terms of relapsing COVID-19, as well as reinfection and/or sustained infection with SARS-CoV-2, have been made for patients with primary antibody deficiencies,^{82,104,116} further underscoring an important role for secreted immunoglobulin in controlling and clearing viral infection and attenuating disease. These findings from analysis of SARS-CoV-2 infection in individuals with congenital B-cell deficiency are also supported by studies of patients with rheumatic/musculoskeletal autoimmune diseases (rheumatoid arthritis, vasculitis, Sjögren syndrome, systemic lupus erythematosus) who are treated with B-cell-depleting therapies such as rituximab. In these cases, therapeutic B-cell depletion can result in high rates of hospital admissions, severe COVID-19 including protracted pneumonia and acute respiratory distress syndrome, and death after SARS-CoV-2 infection.^{141,142} Thus, the inability to generate specific IgG responses to novel antigens as a result of a lack of naive B cells can have dire consequences in the setting of SARS-CoV-2 infection (Fig 3).

This apparent paradox of prolonged illness and viremia but often-milder disease and lower CFR in XLA patients who completely lack B cells may be explained by the nature of the genetic defect. On the one hand, agammaglobulinemia in these patients highlights a key role for specific immunoglobulins in controlling and clearing viral infection, even when responses of innate immune cells and CD4⁺ and CD8⁺ T cells are intact.^{46,83} Indeed, administration of convalescent plasma isolated from previously infected healthy donors or anti-SARS-CoV-2-specific monoclonal antibodies (mAbs) led to rapid reductions in virus load and recovery in XLA—more so than observed with antiviral treatments alone (Fig 3).^{46,53,55,61,85,86,104,139,143} Although convalescent plasma or anti-SARS-CoV-2 mAbs are a logical treatment for XLA patients, similar results have also been reported for other IEI patients who have near-normal B cells and serum immunoglobulin levels but defects in generating functional and protective IgG-dependent humoral immunity. For instance, passive IgG therapy led to dramatic improvements in the clinical course of SARS-CoV-2 infection in patients with pathogenic variants in *NFKB2*,⁴³ *IL2RG*,⁷⁷ *IKBKG* (NEMO),⁷² and *PIK3CD* GOF,⁸² as well as many cases of CVID.^{83,103,104,109,143} In fact, anti-SARS-CoV-2 mAb or convalescent plasma greatly improved virus clearance and disease outcomes when combined with antivirals (eg, remdesivir).^{43,104,143} Thus, while type I IFN-mediated innate immunity is indispensable for containing acute SARS-CoV-2 infection, antibodies are necessary to mitigate prolonged viral infection, minimize disease, and prevent reinfections (Fig 3).

On the other hand, Bruton tyrosine kinase (BTK) deficiency—the genetic cause of XLA—compromises production of

inflammatory cytokines by myeloid cells.¹⁴⁴ Thus, relatively mild pulmonary disease in XLA may result from a lessened cytokine storm after SARS-CoV-2–induced activation of BTK-deficient myeloid cells. This is consistent with findings that some SARS-CoV-2–infected XLA patients have lower serum IL-6 levels than infected individuals in the general population,¹¹¹ observations of mild COVID-19 in patients with B-cell malignancies who were treated with BTK inhibitors,¹⁴⁵ and rapid clinical improvement in COVID-19 patients treated with a BTK inhibitor as a therapeutic intervention.¹⁴⁶ These findings reveal dual roles for BTK in host defense and tissue pathology after SARS-CoV-2 infection. First, B cells and virus-specific antibodies are important for controlling prolonged infection. Second, BTK in myeloid cells may drive the SARS-CoV-2–induced cytokine storm characteristic of severe COVID-19. These findings provide a rationale for the use of passive immunoglobulin serotherapy (intravenous immunoglobulin, mAbs) to expedite virus clearance in IEI characterized by impaired humoral immunity, as well as of BTK inhibitors, Janus kinase (JAK) inhibitors, and tocilizumab (anti-IL-6R)¹⁴⁶⁻¹⁴⁸ to quell SARS-CoV-2–induced production of inflammatory cytokines by myeloid cells. However, it needs to be emphasized that timing of the delivery of these treatments can also influence outcome and efficacy. For instance, if administered too early, JAK inhibitors may attenuate the protective effect of type I IFNs, while delayed treatment with tocilizumab may be ineffectual. Similarly, these interventions may be better suited for some specific types of IEI, particularly as results from clinical trials of these inhibitors in the general population have been variable.

GENE-DIRECTED THERAPIES FOR COVID-19 IN SOME IEI

Delineation of the genetic and serologic causes of severe COVID-19 has led to the implementation of specific therapies in some IEI. For instance, the discovery that inborn errors in type I IFN signaling are a risk factor for severe COVID-19 inspired the use of IFN- α 2a or IFN- β , anti-SARS-CoV-2 mAbs, or convalescent plasma to treat SARS-CoV-2 infection in individuals with pathogenic variants in *TLR3*, *IRF3*, *IRF7*, or *IRF9*,^{68,69,123} which genetically disrupt type I IFN function, or patients with pathogenic *AIRE* variants or incontinentia pigmenti due to pathogenic *IKBKG* variants that result in production of neutralizing anti-type I IFN autoantibodies.^{78,84,149} However, convalescent plasma has also been found to contain neutralizing anti-type I IFN autoantibodies,¹³⁷ which obviously could impact the efficacy of this treatment.

Similarly, plasma exchange was effective at reducing serum levels of neutralizing anti-type I IFN autoantibodies in an APECED patient.⁵⁷ While it is difficult to draw specific conclusions regarding possible therapies for SARS-CoV-2 infection in IEI from these anecdotal investigations, most treated patients exhibited mild disease, experienced rapid resolution of symptoms, and made a full recovery.^{57,68,69,78,84,149} This contrasts with those IEI patients who did not receive specific treatments and experienced severe and even fatal COVID-19.^{120,126,127} Thus, early provision of type I IFN or antibody against SARS-CoV-2 may represent an immunotherapeutic approach to prevent critical pneumonia in patients who are most vulnerable to severe SARS-CoV-2 infection due to disrupted type I IFN–mediated immunity. Furthermore, because anti-type I IFN autoantibodies are

mostly directed against IFN- α and IFN- ω , IFN- β can still be used therapeutically for severe COVID-19 in individuals who develop these neutralizing autoantibodies.

VACCINES AGAINST SARS-CoV-2

The global rollout of several different SARS-CoV-2 vaccines (mRNA, adenoviral based, inactivated virus, viral proteins) has dramatically attenuated COVID-19–associated mortality.¹⁵⁰ These vaccines induce SARS-CoV-2–specific CD4⁺ and CD8⁺ T cells, memory B cells, and neutralizing serum IgG in >95% of healthy donors. Readouts of vaccine-induced immunity generally peaked 2 or 3 weeks after receipt of the second vaccine dose and then either significantly declined (specific IgG titers, CD8⁺ T cells), plateaued (CD4⁺ T cells), or even increased (memory B cells).¹⁵⁰⁻¹⁵² Regardless of these trajectories, SARS-CoV-2–specific adaptive cellular and humoral immunity remained detectable ~6 months after vaccination.¹⁵⁰⁻¹⁵² The magnitude of these vaccine-induced correlates of immunity in healthy individuals was generally comparable to or greater than those observed in convalescent individuals recovering from natural SARS-CoV-2 infection.¹⁵⁰⁻¹⁵²

While these findings are encouraging, several challenges remain in controlling SARS-CoV-2. First, vaccine efficacy declines from 85-95% at 2 to 4 weeks after full vaccination to 20-50% 6 months later, thus revealing an inability to completely resist future infection and highlighting the need for vaccine boosters.^{150,153,154} Second, while successfully reducing disease severity, hospital admissions, and mortality, current vaccines do not effectively prevent SARS-CoV-2 transmission.^{150,155} Third, the emergence of variants of concern—which can arise in immunocompromised individuals¹⁵⁶—compromise vaccine efficacy, with vaccine-induced immunity being significantly reduced against several SARS-CoV-2 variants.^{41,154,157} Thus, COVID-19 continues to represent a significant health risk despite the availability of several SARS-CoV-2 vaccines. Furthermore, findings from studies of IEI have established the importance of SARS-CoV-2–specific neutralizing IgG in preventing severe and prolonged disease as well as reinfection, so it is critical to continue encouraging vaccine and booster uptake in the general population.

EFFICACY OF SARS-CoV-2 VACCINES IN IEI PATIENTS

Many studies have initially assessed the immunogenicity and effectiveness of SARS-CoV-2 vaccines in IEI. The general findings from these studies were that (1) fewer patients mounted SARS-CoV-2–specific IgG (30-75%) and T-cell responses (~50-70%) compared to healthy donors (~95-100%), (2) titers of SARS-CoV-2–specific IgG, efficacy of virus neutralization, and magnitude of T-cell responses were reduced in patients compared to healthy donors, and (3) poor vaccine-induced immunity in patients correlated with reduced numbers of CD4⁺ T cells or memory B cells, low serum IgG and IgA, and older age.^{80,158-173} Importantly, IEI that disrupt type I IFN–mediated immunity or autoantibodies against type I IFN do not impair humoral immune responses to RNA vaccines.¹⁷⁴ Furthermore, despite normal levels of neutralizing IgG, some patients with anti-type I IFN autoantibodies develop breakthrough COVID-19 pneumonia.¹⁷⁵

Overall, these studies established that SARS-CoV-2 vaccines are safe and well tolerated in people with IEI, and that they can induce specific adaptive immune responses, albeit at reduced levels compared to the general population. However, several significant unknowns remain. First, most studies assessed immune responses 2 to 8 weeks after the second vaccine dose. Thus, sustained durability of vaccine-induced immunity in IEI patients against SARS-CoV-2 has not been determined. Second, while almost all vaccine studies measured SARS-CoV-2-specific IgG, only a few determined virus neutralization. Thus, it is unknown whether vaccine-induced immunoglobulin in IEI patients can neutralize the original SARS-CoV-2 strain and emerging variants. Third, specific CD4⁺ and CD8⁺ T-cell responses in vaccinated IEI patients were not assessed in most studies. The paucity of data relating to responses of T-cell subsets impacts our ability to predict vulnerability of individuals with intrinsic T-cell defects to SARS-CoV-2 infection. Fourth, how waning immunity and SARS-CoV-2 variants impact host defense, as well as the capacity of vaccine booster doses to amplify immunity, in IEI patients is unexplored. Fifth, ~80% of all IEI patients assessed in these studies did not have a molecular diagnosis; most had CVID. Thus, it is difficult to (1) delineate cellular and molecular mechanisms underlying impaired immunity in IEI patients, (2) extrapolate these findings from predominantly CVID and antibody-deficient patients to IEI in general, (3) identify which pathways are necessary to elicit robust and long-lived immune responses, and (4) leverage these findings to develop methods to target specific key molecules/pathways to improve host defense against infectious diseases induced by next-generation vaccines. These are issues that need to be addressed in ongoing and future studies.

CONCLUSION

Analysis of individuals with single-gene defects that result in immune dysregulation have defined the fundamental requirements for immune homeostasis and host defense against a broad range of infectious agents. It was upon this foundation that the fields of genetics/genomics, basic and clinical immunology, and infectious diseases combined to make profound advances in unraveling the complexity of SARS-CoV-2 infection and severe COVID-19. Indeed, some of the key discoveries over the past 2 or 3 years have arisen from studying severe COVID-19 in otherwise healthy individuals, as well as in individuals with IEI. These studies established the framework to further define host factors necessary for early innate and sustained adaptive immune-mediated protection against SARS-CoV-2 infection and the establishment of immunologic memory, as well as mechanisms of severe disease and identifying opportunities for therapeutic intervention to manage COVID-19. Despite these breakthrough findings, there remains significant uncertainty regarding SARS-CoV-2 and IEI patients. These include the impact of standard treatments for IEI on immunity against SARS-CoV-2 infection and vaccination (eg, JAK inhibitors, TNF inhibitors, abatacept, rapamycin), long-term effects of SARS-CoV-2 infection/reinfection on IEI patients with autoimmunity and/or malignancy, whether long COVID and neurologic impacts are more prevalent in IEI compared to the general population, and the protective effect of neutralizing antibodies that are accumulating in donor blood products used for immunoglobulin replacement therapy. However, with the rapid pace of the advances already made since we first became aware of SARS-CoV-2, there is no doubt that answers to these questions

—and more—will be delivered as we move into the third year (and, I hope, the last frontier) of this pandemic.

I would like to acknowledge all the clinicians, nurses, caregivers, parents, and patient advocacy groups who have ensured the safety and well-being of patients with IEI during the COVID-19 pandemic. I also want to thank Jean-Laurent Casanova and Helen Su for their leadership of the COVID-19 Human Genetic Effort consortium (www.covidhge.com), as well as their insightful discussions and inspiration since the onset of the pandemic; and Isabelle Meyts and many members of the COVID-19 Human Genetic Effort for their constructive feedback.

Members of the COVID Human Genetic Effort consortium are as follows: Laurent Abel (INSERM U1163, University of Paris, Imagine Institute, Paris, France); Salah Al-Muhsen (Immunology Research Lab, Department of Pediatrics, College of Medicine, King Saud University, Riyadh, Saudi Arabia); Alessandro Aiuti (San Raffaele Telethon Institute for Gene Therapy, IRCCS Ospedale San Raffaele, and Vita Salute San Raffaele University, Milan, Italy); Saleh Al-Muhsen (Immunology Research Laboratory, Department of Pediatrics, College of Medicine and King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia); Fahd Al-Mulla (Dasman Diabetes Institute, Department of Genetics and Bioinformatics, Dasman, Kuwait); Mark S. Anderson (Diabetes Center, University of California, San Francisco, Calif); Evangelos Andreaskos (Biomedical Research Foundation of the Academy of Athens, Athens, Greece); Antonio Novelli (Laboratory of Medical Genetics, IRCCS Bambino Gesù Children's Hospital, Rome, Italy); Andrés A. Arias (Group of Primary Immunodeficiencies, University of Antioquia UdeA, Medellín, Colombia); Hagit Baris Feldman (The Genetics Institute, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel); Alexandre Belot (Pediatric Nephrology, Rheumatology, Dermatology, HFME, Hospices Civils de Lyon, National Referee Centre RAISE, and INSERM U1111, Université de Lyon, Lyon, France); Catherine M. Biggs (Department of Pediatrics, British Columbia Children's Hospital, University of British Columbia, Vancouver, British Columbia, Canada); Ahmed A. Bousfiha (Clinical Immunology Unit, Department of Pediatric Infectious Disease, CHU Ibn Rushd, and LICIA, Laboratoire d'Immunologie Clinique, Inflammation et Allergie, Faculty of Medicine and Pharmacy, Hassan II University, Casablanca, Morocco); Petter Brodin (SciLifeLab, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden); John Christodoulou (Murdoch Children's Research Institute and Department of Paediatrics, University of Melbourne, Melbourne, Australia); Antonio Condino-Neto (Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil); Clifton L. Dalgard (Department of Anatomy, Physiology, and Genetics, Uniformed Services University of the Health Sciences, Bethesda, Md); Sara Espinosa-Padilla (National Institute of Pediatrics, Mexico City, Mexico); Jacques Fellay (School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne; Precision Medicine Unit, Lausanne University Hospital; and University of Lausanne, Lausanne, Switzerland); Carlos Flores (Genomics Division, Instituto Tecnológico y de Energías Renovables [ITER], Santa Cruz de Tenerife; Research Unit, Hospital Universitario NS de Candelaria, Santa Cruz de Tenerife; and CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain); José Luis Franco (Group of Primary Immunodeficiencies, University of Antioquia UdeA, Medellín, Colombia); Antoine Froidure (Pulmonology Department, Cliniques Universitaires Saint-Luc, and Institut de Recherche Expérimentale et Clinique [IREC], Université Catholique de Louvain, Brussels, Belgium); Filomeen Haerynck (Department of Paediatric Immunology and Pulmonology, Centre for Primary Immunodeficiency Ghent [CPIG], PID Research Laboratory, Jeffrey Modell Diagnosis and Research Centre, Ghent University Hospital, Ghent, Belgium); Rabih Halwani (Sharjah Institute of Medical Research, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates [UAE]); Lennart Hammarström (Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden); Sarah E. Henrickson (Department of Pediatrics, Division of Allergy Immunology, Children's Hospital of Philadelphia; and Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa); Elena W. Y. Hsieh (Departments of Pediatrics, Immunology, and

Microbiology, University of Colorado, School of Medicine, Aurora, Colorado); Yuval Itan (Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, and Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY); Timokratsi Karmitros (Bioinformatics and Applied Genomics Unit, Hellenic Pasteur Institute, Athens, Greece); Yu-Lung Lau (Department of Paediatrics and Adolescent Medicine, University of Hong Kong, Hong Kong); Davood Mansouri (Department of Clinical Immunology and Infectious Diseases, National Research Institute of Tuberculosis and Lung Diseases, Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases [NRITLD], Masih Daneshvari Hospital, Shahid Beheshti, University of Medical Sciences, Tehran, Iran); Isabelle Meyts (Department of Pediatrics, University Hospitals Leuven, Department of Microbiology, Immunology, and Transplantation, and Laboratory for Inborn Errors of Immunity, KU Leuven, Leuven, Belgium); Trine H. Mogensen (Department of Biomedicine, Aarhus University, Aarhus, Denmark); Tomohiro Morio (Tokyo Medical and Dental University Hospital, Tokyo, Japan); Lisa F. Ng (A*STAR Infectious Disease Labs, Agency for Science, Technology and Research; and Lee Kong Chian School of Medicine, Nanyang Technology University, Singapore); Luigi D. Notarangelo (National Institute of Allergy and Infectious Diseases [NIAID], National Institutes of Health [NIH], Bethesda, Md); Giuseppe Novelli (Department of Biomedicine and Prevention, Tor Vergata University of Rome, Rome, Italy); Satoshi Okada (Department of Pediatrics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan); Tayfun Ozcelik (Department of Molecular Biology and Genetics, Bilkent University, Bilkent, Ankara, Turkey); Qiang Pan-Hammarström (Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden); Rebeca Perez de Diego (Laboratory of Immunogenetics of Human Diseases, Innate Immunity Group, IdiPAZ Institute for Health Research, La Paz Hospital, Madrid, Spain); Carolina Prando (Faculdades Pequeno Príncipe, Instituto de Pesquisa Pelé Pequeno Príncipe, Curitiba, Brazil); Aurora Pujol (Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute [IDIBELL]), L'Hospitalet de Llobregat; Catalan Institution of Research and Advanced Studies [ICREA]; and Center for Biomedical Research on Rare Diseases [CIBERER], ISCIII, Barcelona, Spain); Laurent Renia (A*STAR Infectious Disease Labs, Agency for Science, Technology and Research; and Lee Kong Chian School of Medicine, Nanyang Technology University, Singapore); Igor Resnick (Department of Medical Genetics, Medical University; and Department of Hematology and BMT, University Hospital St Marina, Varna, Bulgaria); Carlos Rodríguez-Gallego (Department of Immunology, University Hospital of Gran Canaria Dr Negrín, Canarian Health System; and Department of Clinical Sciences, University Fernando Pessoa Canarias, Las Palmas de Gran Canaria, Spain); Vanessa Sancho-Shimizu (Department of Paediatric Infectious Diseases and Virology, Imperial College London; and Centre for Paediatrics and Child Health, Faculty of Medicine, Imperial College London, London, United Kingdom); Mikko R. J. Seppänen (Adult Immunodeficiency Unit, Infectious Diseases, Inflammation Center, University of Helsinki and Helsinki University Hospital; Rare Diseases Center and Pediatric Research Center, Children's Hospital, University of Helsinki; and Helsinki University Hospital, Helsinki, Finland); Anna Shcherbina (Department of Immunology, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology, Moscow, Russia); Andrew L. Snow (Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, Md); Pere Soler-Palacín (Paediatric Infectious Diseases and Immunodeficiencies Unit, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain); Andrés N. Spaan (St Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY; and Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands); Ivan Tancevski (Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria); Stuart G. Tangye (Garvan Institute of Medical Research, Darlinghurst; and St Vincent's Clinical School, Faculty of Medicine, University of New South Wales Sydney, Sydney, Australia); Ahmad Abou Tayoun (Al Jalila Children's Hospital, Dubai, UAE); Sehime G. Temel (Bursa Uludag University, Medical Faculty, Department of Medical Genetics, Bursa, Turkey); Stuart E. Turvey (BC Children's Hospital, The University of British Columbia, Vancouver,

Canada); Mohammed J. Uddin (College of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, UAE; and Cellular Intelligence [CI] Lab, GenomeArc Inc, Toronto, Ontario, Canada); Donald C. Vinh (Department of Medicine, Division of Infectious Diseases, McGill University Health Centre; and Infectious Disease Susceptibility Program, Research Institute, McGill University Health Centre, Montreal, Quebec, Canada); Mayana Zatz (Biosciences Institute, University of São Paulo, São Paulo, Brazil); Keisuke Okamoto (Tokyo Medical and Dental University, Tokyo, Japan); David S. Pelin (Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ); Graziano Pesole (Department of Biosciences, Biotechnology, and Biopharmaceutics, University of Bari A. Moro, Bari, Italy); Diederik van de Beek (Department of Neurology, Amsterdam Neuroscience, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands); Roger Colobran (Hospital Universitari Vall d'Hebron, Barcelona, Spain); Joost Wauters (Department of General Internal Medicine, Medical Intensive Care Unit, University Hospitals Leuven, Leuven, Belgium); Helen C. Su (NIAID, NIH, Bethesda, Md); Jean-Laurent Casanova (Rockefeller University and Howard Hughes Medical Institute, New York, NY; and Necker Hospital for Sick Children and INSERM, Paris, France).

REFERENCES

- Casanova JL, Abel L. Human genetics of infectious diseases: unique insights into immunological redundancy. *Semin Immunol* 2018;36:1-12.
- Casanova JL, Abel L. From rare disorders of immunity to common determinants of infection: following the mechanistic thread. *Cell* 2022;185:3086-103.
- Fischer A, Rausell A. What do primary immunodeficiencies tell us about the essentiality/redundancy of immune responses? *Semin Immunol* 2018;36:13-6.
- Notarangelo LD, Bacchetta R, Casanova JL, Su HC. Human inborn errors of immunity: an expanding universe. *Sci Immunol* 2020.
- Zhang Q, Frange P, Blanche S, Casanova JL. Pathogenesis of infections in HIV-infected individuals: insights from primary immunodeficiencies. *Curr Opin Immunol* 2017;48:122-33.
- Tangye SG, Al-Herz W, Bousfiha A, Cunningham-Rundles C, Franco JL, Holland SM, et al. Human inborn errors of immunity: 2022 update on the classification from the International Union of Immunological Societies Expert Committee. *J Clin Immunol* 2022.
- Rieux-Laucat F, Casanova JL. Immunology. Autoimmunity by haploinsufficiency. *Science* 2014;345:1560-1.
- Ramirez NJ, Posadas-Cantera S, Caballero-Oteyza A, Camacho-Ordóñez N, Grimbacher B. There is no gene for COVID—novel monogenetic causes for primary antibody deficiency. *Curr Opin Immunol* 2021;72:176-85.
- Poyhonen L, Bustamante J, Casanova JL, Jouanguy E, Zhang Q. Life-threatening infections due to live-attenuated vaccines: early manifestations of inborn errors of immunity. *J Clin Immunol* 2019;39:376-90.
- Thalhammer J, Kindle G, Nieters A, Rusch S, Seppänen MRJ, Fischer A, et al. Initial presenting manifestations in 16,486 patients with inborn errors of immunity include infections and noninfectious manifestations. *J Allergy Clin Immunol* 2021;148:1332-41.e5.
- Fischer A, Provot J, Jais JP, Alcais A, Mahlaoui N. Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies. *J Allergy Clin Immunol* 2017;140:1388-93.e8.
- Leiding JW, Ballou M. Redefining precision medicine in disorders of immune dysregulation. *J Allergy Clin Immunol* 2019;7:2801-3.
- Weiss SR. Forty years with coronaviruses. *J Exp Med* 2020.
- Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med* 2020;382:727-33.
- Shields AM, Burns SO, Savic S, Richter AG, UK PIN COVID-19 Consortium. COVID-19 in patients with primary and secondary immunodeficiency: the United Kingdom experience. *J Allergy Clin Immunol* 2021;147:870-5.e1.
- Stokes EK, Zambrano LD, Anderson KN, Marder EP, Raz KM, El Burai Felix S, et al. Coronavirus disease 2019 case surveillance—United States, January 22-May 30, 2020. *MMWR Morb Mortal Wkly Rep* 2020;69:759-65.
- Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. *JAMA* 2020;323:1574-81.
- Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. *J Allergy Clin Immunol* 2020;146:110-8.
- Russell TW, Hellewell J, Jarvis CI, van Zandvoort K, Abbott S, Ratnayake R, et al. Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise ship. February 2020. *Euro Surveill* 2020;25:2000256.

20. Abers MS, Delmonte OM, Ricotta EE, Fintzi J, Fink DL, de Jesus AAA, et al. An immune-based biomarker signature is associated with mortality in COVID-19 patients. *JCI Insight* 2021;6:e144455.
21. Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. *Nat Rev Immunol* 2020;20:355-62.
22. Herold T, Jurinovic V, Arnreich C, Lipworth BJ, Hellmuth JC, von Bergwelt-Baildon M, et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. *J Allergy Clin Immunol* 2020;146:128-36.e4.
23. Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. *Nat Med* 2020;26:1636-43.
24. Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. *Science* 2020;369:718-24.
25. Quartuccio L, Sonaglia A, Pecori D, Peghin M, Fabris M, Tascini C, et al. Higher levels of IL-6 early after tocilizumab distinguish survivors from nonsurvivors in COVID-19 pneumonia: a possible indication for deeper targeting of IL-6. *J Med Virol* 2020;92:2852-6.
26. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med* 2020;46:846-8.
27. Holter JC, Pischke SE, de Boer E, Lind A, Jenun S, Holten AR, et al. Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients. *Proc Natl Acad Sci U S A* 2020;117:25018-25.
28. Ramlall V, Thangaraj PM, Meydan C, Foox J, Butler D, Kim J, et al. Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection. *Nat Med* 2020;26:1609-15.
29. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. *J Clin Invest* 2020;130:2620-9.
30. Hou H, Zhang Y, Tang G, Luo Y, Liu W, Cheng C, et al. Immunologic memory to SARS-CoV-2 in convalescent COVID-19 patients at 1 year postinfection. *J Allergy Clin Immunol* 2021;148:1481-92.e2.
31. Breton G, Mendoza P, Hagglof T, Oliveira TY, Schaefer-Babajew D, Gaebler C, et al. Persistent cellular immunity to SARS-CoV-2 infection. *J Exp Med* 2021.
32. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. *Science* 2021.
33. Bilich T, Nelde A, Heitmann JS, Maringer Y, Roerden M, Bauer J, et al. T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals. *Sci Transl Med* 2021.
34. Moriyama S, Adachi Y, Sato T, Tonouchi K, Sun L, Fukushi S, et al. Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants. *Immunity* 2021;54:1841-52.e4.
35. Sherina N, Piralla A, Du L, Wan H, Kumagai-Braesch M, Andrej J, et al. Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-8 months after the infection. *Med (N Y)* 2021;2:281-95.e4.
36. Hartley GE, Edwards ESJ, Aui PM, Varese N, Stojanovic S, McMahon J, et al. Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. *Sci Immunol* 2020;5:eabf8891.
37. Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. *Science* 2020;370:1227-30.
38. Balachandran H, Phetsouphanh C, Agapiou D, Adhikari A, Rodrigo C, Hammoud M, et al. Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4⁺ T cell responses. *Cell Rep* 2022;38:110345.
39. Abayasingam A, Balachandran H, Agapiou D, Hammoud M, Rodrigo C, Keoshkerian E, et al. Long-term persistence of RBD⁺ memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection. *Cell Rep Med* 2021;2:100228.
40. Chia WN, Zhu F, Ong SWX, Young BE, Fong SW, Le Bert N, et al. Dynamics of SARS-CoV-2 neutralizing antibody responses and duration of immunity: a longitudinal study. *Lancet Microbe* 2021;2:e240-9.
41. Hirabara SM, Serdan TDA, Gorjao R, Masi LN, Pithon-Curi TC, Covas DT, et al. SARS-CoV-2 variants: differences and potential of immune evasion. *Front Cell Infect Microbiol* 2021;11:781429.
42. Abolhassani H, Landegren N, Bastard P, Materna M, Modaresi M, Du L, et al. Inherited *IFNAR1* deficiency in a child with both critical COVID-19 pneumonia and multisystem inflammatory syndrome. *J Clin Immunol* 2022;42:471-83.
43. Abraham RS, Marshall JM, Kuehn HS, Rueda CM, Gibbs A, Guider W, et al. Severe SARS-CoV-2 disease in the context of a NF-kappaB2 loss-of-function pathogenic variant. *J Allergy Clin Immunol* 2021;147:532-44.e1.
44. Beccuti G, Ghizzoni L, Cambria V, Codullo V, Sacchi P, Lovati E, et al. A COVID-19 pneumonia case report of autoimmune polyendocrine syndrome type 1 in Lombardy, Italy: letter to the editor. *J Endocrinol Invest* 2020;43:1175-7.
45. Bucciol G, Moens L, Corveleyn A, Dreesman A, Meyts I. A novel kindred with MyD88 deficiency. *J Clin Immunol* 2022;42:885-8.
46. Buckland MS, Galloway JB, Fhogartaigh CN, Meredith L, Provine NM, Bloor S, et al. Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report. *Nat Commun* 2020;11:6385.
47. Castano-Jaramillo LM, Yamazaki-Nakashimada MA, Scheffler Mendoza SC, Bustamante-Ogando JC, Espinosa-Padilla SE, Lugo Reyes SO. A male infant with COVID-19 in the context of ARPC1B deficiency. *Pediatr Allergy Immunol* 2021;32:199-201.
48. Cenciarelli S, Calbi V, Barzaghi F, Bernardo ME, Oltolini C, Migliavacca M, et al. Mild SARS-CoV-2 infection after gene therapy in a child with Wiskott-Aldrich syndrome: a case report. *Front Immunol* 2020;11:603428.
49. Gabryszewski SJ, England RN, Sun D, Gentile TL, Hochgertel W, Yjonouchi S, et al. Self-limited COVID-19 in a patient with artemis hypomorphic SCID. *J Clin Immunol* 2021.
50. Guisado Hernandez P, Blanco Lobo P, Villaoslada I, de Felipe B, Lucena JM, Martin Gutierrez G, et al. SARS-CoV-2 infection in a pediatric *STAT1* GOF patient under ruxolitinib therapy—a matter of balance? *J Clin Immunol* 2021.
51. Gupta S, Agrawal S, Sandoval A, Su H, Tran M, Demirdag Y. SARS-CoV-2-specific and functional cytotoxic CD8 cells in primary antibody deficiency: natural infection and response to vaccine. *J Clin Immunol* 2022.
52. Gupta S, Su H, Narsai T, Agrawal S. SARS-CoV-2-associated T-cell responses in the presence of humoral immunodeficiency. *Int Arch Allergy Immunol* 2021;182:195-209.
53. Iaboni A, Wong N, Betschel SD. A patient with X-linked agammaglobulinemia and COVID-19 infection treated with remdesivir and convalescent plasma. *J Clin Immunol* 2021;41:923-5.
54. Jin H, Moss R, Reed JC, Hertzberg E, Cruz MR, Akkoyun E, et al. IFN-gamma receptor 2 deficiency initial mimicry of multisystem inflammatory syndrome in children (MIS-C). *J Allergy Clin Immunol Pract* 2021;9:989-92.e1.
55. Jin H, Reed JC, Liu STH, Ho HE, Lopes JP, Ramsey NB, et al. Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma. *J Allergy Clin Immunol Pract* 2020;8:3594-6.e3.
56. Khammohammadi S, Rezaei N, Khazaei M, Shirvani A. A case of autosomal recessive interferon alpha/beta receptor alpha chain (*IFNAR1*) deficiency with severe COVID-19. *J Clin Immunol* 2022;42:19-24.
57. Lemarquis A, Campbell T, Aranda-Guillen M, Hennings V, Brodin P, Kampe O, et al. Severe COVID-19 in an APS1 patient with interferon autoantibodies treated with plasmapheresis. *J Allergy Clin Immunol* 2021;148:96-8.
58. London J, Boutboul D, Lacombe K, Pirenne F, Heym B, Zeller V, et al. Severe COVID-19 in patients with B cell lymphocytosis and response to convalescent plasma therapy. *J Clin Immunol* 2021;41:356-61.
59. Mantravadi V, Nguyen ST, Morley SC, Bednarski JJ, Kitcharoensakkul M, Cooper MA. Recovery from COVID-19 in a child with chronic granulomatous disease and T cell lymphopenia. *J Clin Immunol* 2021;41:23-5.
60. Milosevic I, Jovanovic J, Stevanovic O. Atypical course of COVID-19 in patient with Bruton agammaglobulinemia. *J Infect Dev Ctries* 2020;14:1248-51.
61. Mira E, Yarce OA, Ortega C, Fernandez S, Pascual NM, Gomez C, et al. Rapid recovery of a SARS-CoV-2-infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma. *J Allergy Clin Immunol Pract* 2020;8:2793-5.
62. Muller J, Wang A, Feldweg A. A fatal case of coronavirus disease 2019 in a patient with common variable immunodeficiency. *Ann Allergy Asthma Immunol* 2021;126:90-2.
63. Narahari PG, Gebbia J, Alperstein W, Kleiner G, Gans M. Post-SARS-CoV-2 atypical inflammatory syndrome in a toddler with X-linked inhibitor of apoptosis deficiency after stem cell transplant. *J Clin Immunol* 2022.
64. Sanchez Clemente N, Penner J, Breuer J, Ip W, Booth C. Case report: a severe paediatric presentation of COVID-19 in APDS2 immunodeficiency. *Front Immunol* 2022;13:881259.
65. Schmidt A, Peters S, Knaus A, Sabir H, Hamsen F, Maj C, et al. *TBKI* and *TNFRSF13B* mutations and an autoinflammatory disease in a child with lethal COVID-19. *NPJ Genom Med* 2021;6:55.
66. Soresina A, Moratto D, Chiarini M, Paolillo C, Baresi G, Foca E, et al. Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover. *Pediatr Allergy Immunol* 2020;31:565-9.
67. Vignesh P, Mondal S, Sudhakar M, Sharma YK, Bansal A, Singh M, et al. SARS-CoV-2 infection in a child with severe congenital neutropenia. *J Clin Immunol* 2021;41:1165-8.

68. Levy R, Bastard P, Lanternier F, Lecuit M, Zhang SY, Casanova JL. IFN- α 2a therapy in two patients with inborn errors of *TLR3* and *IRF3* infected with SARS-CoV-2. *J Clin Immunol* 2021;41:26-7.
69. Levy R, Zhang P, Bastard P, Dorgham K, Melki I, Hadchouel A, et al. Monoclonal antibody-mediated neutralization of SARS-CoV-2 in an IRF9-deficient child. *Proc Natl Acad Sci U S A* 2021.
70. Al-Saud B, Hazzazi KM, Mohammed R, Al Najjar A, Al Hazmi T, Monies D, et al. SARS-CoV-2-related acute respiratory distress syndrome uncovers a patient with severe combined immunodeficiency disease. *J Clin Immunol* 2021.
71. Aljaberi R, Wishah K. Positive outcome in a patient with coronavirus disease 2019 and common variable immunodeficiency after intravenous immunoglobulin. *Ann Allergy Asthma Immunol* 2020;125:349-50.
72. Alkan G, Artac H, Oz SKT, Emiroglu M. Management of COVID-19 pneumonia in a child with NEMO deficiency. *Immunol Res* 2021;69:391-3.
73. Almontasheri A, Al-Husayni F, Alsuraifi AK, Binyahib H, Albanna AS. The clinical course of COVID-19 pneumonia in a 19-year-old man on intravenous immunoglobulin replacement therapy for X-linked agammaglobulinemia. *Am J Case Rep* 2021;22:e929447.
74. Bozonnet A, Assan F, LeGoff J, Bourrat E, Bachelez H. SARS-CoV-2 infection inducing severe flare up of deficiency of interleukin thirty-six (IL-36) receptor antagonist (DITRA) resulting from a mutation invalidating the activating cleavage site of the IL-36 receptor antagonist. *J Clin Immunol* 2021.
75. Fill L, Hadney L, Graven K, Persaud R, Hostoffer R. The clinical observation of a patient with common variable immunodeficiency diagnosed as having coronavirus disease 2019. *Ann Allergy Asthma Immunol* 2020;125:112-4.
76. Lee PY, Platt CD, Weeks S, Grace RF, Maher G, Gauthier K, et al. Immune dysregulation and multisystem inflammatory syndrome in children (MIS-C) in individuals with haploinsufficiency of *SOCS1*. *J Allergy Clin Immunol* 2020;146:1194-200.e1.
77. van Oers NSC, Hanners NW, Sue PK, Aquino V, Li QZ, Schoggins JW, et al. SARS-CoV-2 infection associated with hepatitis in an infant with X-linked severe combined immunodeficiency. *Clin Immunol* 2021;224:108662.
78. Bastard P, Levy R, Henriquez S, Bodemer C, Szwebel TA, Casanova JL. Interferon-beta therapy in a patient with incontinentia pigmenti and autoantibodies against type I IFNs infected with SARS-CoV-2. *J Clin Immunol* 2021;41:931-3.
79. Penafiel Vicuna AK, Yamazaki Nakashimada M, Leon Lara X, Mendieta Flores E, Nunez Nunez ME, Lona-Reyes JC, et al. Mendelian susceptibility to mycobacterial disease: retrospective clinical and genetic study in Mexico. *J Clin Immunol* 2022.
80. Bloomfield M, Parackova Z, Hanzlikova J, Lastovicka J, Sediva A. Immunogenicity and safety of COVID-19 mRNA vaccine in *STAT1* GOF patients. *J Clin Immunol* 2022;42:266-9.
81. Mahmood HZ, Madhavarapu S, Almuqamam M. Varying illness severity in patients with MyD88 deficiency infected with coronavirus SARS-CoV-2. *Pediatrics* 2021;147:453-4.
82. Rivalta B, Amodio D, Giancotta C, Santilli V, Pacillo L, Zangari P, et al. Case report: successful treatment with monoclonal antibodies in one apds patient with prolonged SARS-CoV-2 infection not responsive to previous lines of treatment. *Front Immunol* 2022;13:891274.
83. Steiner S, Schwarz T, Corman VM, Gebert L, Kleinschmidt MC, Wald A, et al. SARS-CoV-2 T cell response in severe and fatal COVID-19 in primary antibody deficiency patients without specific humoral immunity. *Front Immunol* 2022;13:840126.
84. Schidlowski L, Iwamura APD, Covid SUD, Condino-Neto A, Prando C. Diagnosis of APS-1 in two siblings following life-threatening COVID-19 pneumonia. *J Clin Immunol* 2022;42:749-52.
85. Palomba E, Carrabba M, Zuglian G, Alagna L, Saltini P, Fortina V, et al. Treatment of SARS-CoV-2 relapse with remdesivir and neutralizing antibodies cocktail in a patient with X-linked agammaglobulinemia. *Int J Infect Dis* 2021;110:338-40.
86. Hovey JG, Tolbert D, Howell D. Bruton's agammaglobulinemia and COVID-19. *Cureus* 2020;12:e11701.
87. Duncan CJA, Skouboe MK, Howarth S, Hollensen AK, Chen R, Borresen ML, et al. Life-threatening viral disease in a novel form of autosomal recessive IFNAR2 deficiency in the Arctic. *J Exp Med* 2022;219.
88. Reiff DD, Zhang M, Smitherman EA, Mannion ML, Stoll ML, Weiser P, et al. A rare *STXB2* mutation in severe COVID-19 and secondary cytokine storm syndrome. *Life (Basel)* 2022;12.
89. Delavari S, Abolhassani H, Abolnezhadian F, Babaha F, Iranparast S, Ahanchian H, et al. Impact of SARS-CoV-2 pandemic on patients with primary immunodeficiency. *J Clin Immunol* 2021;41:345-55.
90. Abolhassani H, Vosughimotlagh A, Asano T, Landegren N, Boisson B, Delavari S, et al. X-linked TLR7 deficiency underlies critical COVID-19 pneumonia in a male patient with ataxia-telangiectasia. *J Clin Immunol* 2022;42:1-9.
91. Abolhassani H, Delavari S, Landegren N, Shokri S, Bastard P, Du L, et al. Genetic and immunological evaluation of children with inborn errors of immunity and severe or critical COVID-19. *J Allergy Clin Immunol* 2022.
92. Esenboga S, Ocak M, Akarsu A, Bildik HN, Cagdas D, Iskit AT, et al. COVID-19 in patients with primary immunodeficiency. *J Clin Immunol* 2021.
93. Guven SC, Erden A, Karakas O, Armagan B, Usul E, Omma A, et al. COVID-19 outcomes in patients with familial Mediterranean fever: a retrospective cohort study. *Rheumatol Int* 2021;41:715-9.
94. Karakoc Aydiner E, Bilgic Eltan S, Babayeva R, Aydiner O, Kepenekli E, Kulkisa B, et al. Adverse COVID-19 outcomes in immune deficiencies: inequality exists between subclasses. *Allergy* 2022;77:282-95.
95. Goudouris ES, Pinto-Mariz F, Mendonca LO, Aranda CS, Guimaraes RR, Kokron C, et al. Outcome of SARS-CoV-2 infection in 121 patients with inborn errors of immunity: a cross-sectional study. *J Clin Immunol* 2021.
96. Grumach AS, Goudouris E, Dortas Junior S, Marcelino FC, Alonso MLO, Martins RO, et al. COVID-19 affecting hereditary angioedema patients with and without C1 inhibitor deficiency. *J Allergy Clin Immunol Pract* 2021;9:508-10.
97. Marcus N, Frizinsky S, Hagin D, Ovadia A, Hanna S, Farkash M, et al. Minor clinical impact of COVID-19 pandemic on patients with primary immunodeficiency in Israel. *Front Immunol* 2020;11:614086.
98. Quinti I, Lougaris V, Milito C, Cinetto F, Pecoraro A, Mezzaroma I, et al. A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia. *J Allergy Clin Immunol* 2020;146:211-23.e4.
99. Milito C, Lougaris V, Giardino G, Punziano A, Vultaggio A, Carrabba M, et al. Clinical outcome, incidence, and SARS-CoV-2 infection-fatality rates in Italian patients with inborn errors of immunity. *J Allergy Clin Immunol Pract* 2021;9:2904-6.e2.
100. Giardino G, Milito C, Lougaris V, Punziano A, Carrabba M, Cinetto F, et al. The impact of SARS-CoV-2 infection in patients with inborn errors of immunity: the experience of the Italian Primary Immunodeficiencies Network (IPINet). *J Clin Immunol* 2022.
101. Milito C, Cinetto F, Palladino A, Garzi G, Punziano A, Lagnese G, et al. Mortality in severe antibody deficiencies patients during the first two years of the COVID-19 pandemic: vaccination and monoclonal antibodies efficacy. *Biomedicines* 2022.
102. Deya-Martinez A, Garcia-Garcia A, Gonzalez-Navarro EA, Yiyi L, Vlagea A, Jordan I, et al. COVID-19 in children and young adults with moderate/severe inborn errors of immunity in a high burden area in pre-vaccine era. *Clin Immunol* 2021;230:108821.
103. Shields AM, Anantharachagan A, Arumugamani G, Baker K, Bahal S, Baxendale H, et al. Outcomes following SARS-CoV-2 infection in patients with primary and secondary immunodeficiency in the UK. *Clin Exp Immunol* 2022.
104. Brown LK, Moran E, Goodman A, Baxendale H, Birmingham W, Buckland M, et al. Treatment of chronic or relapsing COVID-19 in immunodeficiency. *J Allergy Clin Immunol* 2022;149:557-61.e1.
105. Castano-Jaramillo LM, Yamazaki-Nakashimada MA, O'Farrill-Romanillos PM, Muzquiz Zermeno D, Scheffler Mendoza SC, Venegas Montoya E, et al. COVID-19 in the context of inborn errors of immunity: a case series of 31 patients from Mexico. *J Clin Immunol* 2021.
106. Drabe CH, Hansen AE, Rasmussen LD, Larsen OD, Moller A, Mogensen TH, et al. Low morbidity in Danish patients with common variable immunodeficiency disorder infected with severe acute respiratory syndrome coronavirus 2. *Infect Dis (Lond)* 2021;53:953-8.
107. Katzenstein TL, Rasmussen LD, Drabe CH, Larsen CS, Hansen AE, Staerkind M, et al. Outcome of SARS-CoV-2 infection among patients with common variable immunodeficiency and a matched control group: a Danish nationwide cohort study. *Front Immunol* 2022;13:994253.
108. Koltan S, Zietkiewicz M, Grzesk E, Becht R, Berdej-Szczot E, Cienkusz M, et al. COVID-19 in unvaccinated patients with inborn errors of immunity-polish experience. *Front Immunol* 2022;13:953700.
109. Milota T, Sobotkova M, Smetanova J, Bloomfield M, Vydlakova J, Chovancova Z, et al. Risk factors for severe COVID-19 and hospital admission in patients with inborn errors of immunity—results from a multicenter nationwide study. *Front Immunol* 2022;13:835770.
110. Bourguiba R, Delplanque M, Vinit C, Ackermann F, Savey L, Grateau G, et al. Clinical course of COVID-19 in a cohort of 342 familial Mediterranean fever patients with a long-term treatment by colchicine in a French endemic area. *Ann Rheum Dis* 2020.
111. Ho HE, Mathew S, Peluso MJ, Cunningham-Rundles C. Clinical outcomes and features of COVID-19 in patients with primary immunodeficiencies in New York City. *J Allergy Clin Immunol Pract* 2021;9:490-3.e2.
112. Cohen B, Rubinstein R, Gans MD, Deng L, Rubinstein A, Eisenberg R. COVID-19 infection in 10 common variable immunodeficiency patients in New York City. *J Allergy Clin Immunol Pract* 2021;9:504-7.e1.

113. Greenmyer JR, Joshi AY. COVID-19 in COVID: a case series of 17 patients. *J Clin Immunol* 2022;42:29-31.
114. Kuster JK, Unlu S, Makin TA, Par-Young J, Simonov M, Shafi S, et al. Low IgG trough and lymphocyte subset counts are associated with hospitalization for COVID-19 in patients with primary antibody deficiency. *J Allergy Clin Immunol Pract* 2022;10:633-6.e3.
115. Meyts I, Buccioli G, Quinti I, Neven B, Fischer A, Seoane E, et al. Coronavirus disease 2019 in patients with inborn errors of immunity: an international study. *J Allergy Clin Immunol* 2021;147:520-31.
116. Marcus N, Ashkenazi-Hoffnung L, Ovadia A, Dalal I, Yoffe S, Kropach N, et al. SARS-CoV-2 symptomatic reinfection among patients with primary antibody deficiency. *J Allergy Clin Immunol Pract* 2022;10:1907-9.
117. Terlizzi V, Motisi MA, Pellegrino R, Padoan R, Chiappini E. Risk factors for severe COVID-19 in people with cystic fibrosis: a systematic review. *Front Pediatr* 2022;10:958658.
118. Bastard P, Orlova E, Sozaeva L, Levy R, James A, Schmitt MM, et al. Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1. *J Exp Med* 2021;218.
119. Tangye SG, Buccioli G, Meyts I. Mechanisms underlying host defense and disease pathology in response to severe acute respiratory syndrome (SARS)-CoV2 infection: insights from inborn errors of immunity. *Curr Opin Allergy Clin Immunol* 2021;21:515-24.
120. Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. *Science* 2020;370:eabd4570.
121. Puel A, Bastard P, Bustamante J, Casanova JL. Human autoantibodies underlying infectious diseases. *J Exp Med* 2022.
122. Meisel C, Akbil B, Meyer T, Lankes E, Corman VM, Staudacher O, et al. Mild COVID-19 despite autoantibodies against type I IFNs in autoimmune polyendocrine syndrome type 1. *J Clin Invest* 2021.
123. Campbell TM, Liu Z, Zhang Q, Moncada-Velez M, Covill LE, Zhang P, et al. Respiratory viral infections in otherwise healthy humans with inherited IRF7 deficiency. *J Exp Med* 2022.
124. van der Made CI, Simons A, Schuurs-Hoeijmakers J, van den Heuvel G, Mantere T, Kersten S, et al. Presence of genetic variants among young men with severe COVID-19. *JAMA* 2020;324:663-73.
125. Asano T, Boisson B, Onodi F, Matuozzo D, Moncada-Velez M, Maglorius Renkilaraj MRL, et al. X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. *Sci Immunol* 2021.
126. Zhang Q, Matuozzo D, Le Pen J, Lee D, Moens L, Asano T, et al. Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia. *J Exp Med* 2022.
127. Zhang Q, Bastard P, Effort CHG, Cobat A, Casanova JL. Human genetic and immunological determinants of critical COVID-19 pneumonia. *Nature* 2022.
128. Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. *Science* 2020.
129. Troya J, Bastard P, Planas-Serra L, Ryan P, Ruiz M, de Carranza M, et al. Neutralizing autoantibodies to type I IFNs in >10% of patients with severe COVID-19 pneumonia hospitalized in Madrid, Spain. *J Clin Immunol* 2021;41:914-22.
130. al eBastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years and account for ~20% of COVID-19 deaths. *Sci Immunol* 2021.
131. de Prost N, Bastard P, Arrestier R, Fourati S, Mahevas M, Burrel S, et al. Plasma exchange to rescue patients with autoantibodies against type I interferons and life-threatening COVID-19 pneumonia. *J Clin Immunol* 2021;41:536-44.
132. Abers MS, Rosen LB, Delmonte OM, Shaw E, Bastard P, Imberti L, et al. Neutralizing type-I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVID-19. *Immunol Cell Biol* 2021.
133. Manry J, Bastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q, et al. The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. *Proc Natl Acad Sci U S A* 2022;119:e2200413119.
134. Eto S, Nukui Y, Tsumura M, Nakagawa Y, Kashimada K, Mizoguchi Y, et al. Neutralizing type I Interferon autoantibodies in Japanese patients with severe COVID-19. *J Clin Immunol* 2022.
135. van der Wijst MGP, Vazquez SE, Hartoularos GC, Bastard P, Grant T, Bueno R, et al. Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19. *Sci Transl Med* 2021;13:eab2624.
136. Goncalves D, Mezidi M, Bastard P, Perret M, Saker K, Fabien N, et al. Antibodies against type I interferon: detection and association with severe clinical outcome in COVID-19 patients. *Clin Transl Immunology* 2021;10:e1327.
137. Raadsen MP, Gharbharan A, Jordans CCE, Mykityn AZ, Lamers MM, van den Doel PB, et al. Interferon-alpha2 auto-antibodies in convalescent plasma therapy for COVID-19. *J Clin Immunol* 2022;42:232-9.
138. Mathian A, Breillat P, Dorgham K, Bastard P, Charre C, Lhote R, et al. Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-alpha. *Ann Rheum Dis* 2022.
139. Nguyen H, Salkeld J, Agarwal S, Goodman A. Compassionate use of REGN-COV2 in the treatment of COVID-19 in a patient with impaired humoral immunity. *Clin Infect Pract* 2021;12:100089.
140. Loh SY, Bassett J, Hoodless EJ, Walshaw M. Possible COVID-19 reinfection in a patient with X-linked agammaglobulinemia. *BMJ Case Rep* 2021.
141. Daoussi D, Leonidou L, Kalogeropoulou C, Paliogianni F, Tzouveleki A. Protracted severe COVID-19 pneumonia following rituximab treatment: caution needed. *Rheumatol Int* 2021;41:1839-43.
142. Loarce-Martos J, Garcia-Fernandez A, Lopez-Gutierrez F, Garcia-Garcia V, Calvo-Sanz L, Del Bosque-Granero I, et al. High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study. *Rheumatol Int* 2020;40:2015-21.
143. Lang-Meli J, Fuchs J, Mathe P, Ho HE, Kern L, Jaki L, et al. Case series: convalescent plasma therapy for patients with COVID-19 and primary antibody deficiency. *J Clin Immunol* 2022;42:253-65.
144. Lougaris V, Baronio M, Vitali M, Tampella G, Cattalini M, Tassone L, et al. Bruton tyrosine kinase mediates TLR9-dependent human dendritic cell activation. *J Allergy Clin Immunol* 2014;133:1644-50.e4.
145. Treon SP, Castillo JJ, Skarbnik AP, Soumerai JD, Ghobrial IM, Guerrero ML, et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. *Blood* 2020;135:1912-5.
146. Roschewski M, Lionakis MS, Sharman JP, Roswarski J, Goy A, Monticelli MA, et al. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. *Sci Immunol* 2020;5.
147. Roumier M, Paule R, Vallee A, Rohmer J, Ballester M, Brun AL, et al. Tocilizumab for severe worsening COVID-19 pneumonia: a propensity score analysis. *J Clin Immunol* 2021;41:303-14.
148. Jamilloux Y, Henry T, Belot A, Viel S, Fauter M, El Jammal T, et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. *Autoimmun Rev* 2020;19:102567.
149. Ferré ENN, Schmitt MM, Ochoa S, Rosen LB, Shaw ER, Burbelo PD, et al. SARS-CoV-2 spike protein-directed monoclonal antibodies may ameliorate COVID-19 complications in APECED patients. *Front Immunol* 2021;12:720205.
150. Barouch DH. COVID-19 vaccines—immunity, variants, boosters. *N Engl J Med* 2022;387:1011-20.
151. Sette A, Crotty S. Immunological memory to SARS-CoV-2 infection and COVID-19 vaccines. *Immunol Rev* 2022;310:27-46.
152. Zhang Z, Mateus J, Coelho CH, Dan JM, Moderbacher CR, Galvez RI, et al. Humoral and cellular immune memory to four COVID-19 vaccines. *Cell* 2022;185:2434-51.e17.
153. Chemaitelly H, Tang P, Hasan MR, AlMukdad S, Yassine HM, Benslimane FM, et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. *N Engl J Med* 2021;385:e83.
154. Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. *N Engl J Med* 2022;386:1532-46.
155. Siddle KJ, Krasnikova LA, Moreno GK, Schaffner SF, Vostok J, Fitzgerald NA, et al. Transmission from vaccinated individuals in a large SARS-CoV-2 Delta variant outbreak. *Cell* 2022;185:485-92.e10.
156. Wilkinson SAJ, Richter A, Casey A, Osman H, Mirza JD, Stockton J, et al. Recurrent SARS-CoV-2 mutations in immunodeficient patients. *Virus Evol* 2022;8:veac050.
157. Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, et al. SARS-CoV-2 variants, spike mutations and immune escape. *Nat Rev Microbiol* 2021;19:409-24.
158. Amodio D, Ruggiero A, Sgrulletti M, Pighi C, Cotugno N, Medri C, et al. Humoral and cellular response following vaccination with the BNT162b2 mRNA COVID-19 vaccine in patients affected by primary immunodeficiencies. *Front Immunol* 2021;12:727850.
159. Antoli A, Rocamora-Blanch G, Framil M, Mas-Bosch V, Navarro S, Bermudez C, et al. Evaluation of humoral and cellular immune responses to the SARS-CoV-2 vaccine in patients with common variable immunodeficiency phenotype and patient receiving B-cell depletion therapy. *Front Immunol* 2022;13:895209.
160. Arroyo-Sanchez D, Cabrera-Marante O, Laguna-Goya R, Almendro-Vazquez P, Carretero O, Gil-Etayo FJ, et al. Immunogenicity of anti-SARS-CoV-2 vaccines in common variable immunodeficiency. *J Clin Immunol* 2022;42:240-52.
161. Barmettler S, DiGiacomo DV, Yang NJ, Lam T, Naranbhai V, Dighe AS, et al. Response to severe acute respiratory syndrome coronavirus 2 initial series and additional dose vaccine in patients with predominant antibody deficiency. *J Allergy Clin Immunol Pract* 2022;10:1622-34.e4.

162. Bergman P, Blennow O, Hansson L, Mielke S, Nowak P, Chen P, et al. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. *EBioMedicine* 2021;74:103705.
163. Bergman P, Wullimann D, Gao Y, Wahren Borgstrom E, Norlin AC, Lind Enoksson S, et al. Elevated CD21^{low} B cell frequency is a marker of poor immunity to Pfizer-BioNTech BNT162b2 mRNA vaccine against SARS-CoV-2 in patients with common variable immunodeficiency. *J Clin Immunol* 2022;42:716-27.
164. Carrabba M, Baselli LA, Consonni D, Ceriotti F, Fabio G. Responses to SARS-CoV-2 vaccines of patients with common variable immune deficiencies and X-linked agammaglobulinemia. *J Clin Immunol* 2022.
165. Delmonte OM, Bergerson JRE, Burbelo PD, Durkee-Shock JR, Dobbs K, Bosticardo M, et al. Antibody responses to the SARS-CoV-2 vaccine in individuals with various inborn errors of immunity. *J Allergy Clin Immunol* 2021;148:1192-7.
166. Hagin D, Freund T, Navon M, Halperin T, Adir D, Marom R, et al. Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity. *J Allergy Clin Immunol* 2021.
167. Pham MN, Murugesan K, Banaei N, Pinsky BA, Tang M, Hoyte E, et al. Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects. *J Allergy Clin Immunol* 2022;149:907-11.e3.
168. Ponsford MJ, Evans K, Carne EM, Jolles S. COVID-19 vaccine uptake and efficacy in a national immunodeficiency cohort. *J Clin Immunol* 2022;42:728-31.
169. Pulvirenti F, Fernandez Salinas A, Miloto C, Terreri S, Piano Mortari E, Quintarelli C, et al. B cell response induced by SARS-CoV-2 infection is boosted by the BNT162b2 vaccine in primary antibody deficiencies. *Cells*; 2021.
170. Romano C, Esposito S, Donnarumma G, Marrone A. Detection of neutralizing anti-severe acute respiratory syndrome coronavirus 2 antibodies in patients with common variable immunodeficiency after immunization with messenger RNA vaccines. *Ann Allergy Asthma Immunol* 2021;127:499-501.
171. Salinas AF, Mortari EP, Terreri S, Quintarelli C, Pulvirenti F, Di Cecca S, et al. SARS-CoV-2 vaccine induced atypical immune responses in antibody defects: everybody does their best. *J Clin Immunol* 2021;41:1709-22.
172. Shields AM, Faustini SE, Hill HJ, Al-Taei S, Tanner C, Ashford F, et al. SARS-CoV-2 vaccine responses in individuals with antibody deficiency: findings from the COV-AD study. *J Clin Immunol* 2022.
173. van Leeuwen LPM, GeurtsvanKessel CH, Ellerbroek PM, de Bree GJ, Potjewijd J, Rutgers A, et al. Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity. *J Allergy Clin Immunol* 2022;149:1949-57.
174. Sokal A, Bastard P, Chappert P, Barba-Spaeth G, Fourati S, Vanderberghe A, et al. Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination. *J Exp Med* 2022.
175. Bastard P, Vazquez S, Liu J, Laurie MT, Wang CY, Gervais A, et al. Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs. *Sci Immunol* 2022.
176. Khalid M, Urban A, Darnel D, Freeman A. Clinical outcomes of SARS-CoV2 infection in STAT3 deficiency. *J Clin Immunol* 2021;41:abstract 83.
177. Ochoa S, Rosen L, Lionakis M, Uzel G, Suez D. COVID-19 in 3 patients with CTLA4 haploinsufficiency and absence of autoantibodies to type I interferons. *J Clin Immunol* 2021.